Crown Princess Mette-Marit of Norway is on sick leave for at least a week. The Norwegian Royal House announced on Oct. 23 that "due to side effects of the medicines the Crown Princess must take ...

How to Choose the Best Hair Loss Treatment for You Finding the right hair loss treatment depends on the type and severity of your hair loss. With so many options available, it’s important to ...

The goal in treating ulcerative colitis is to reduce the inflammation, hopefully leading to remission. The two leading treatment options are medication and surgery. Approximately 70 percent of ...

"This could provide a better understanding of the occurrence of chronic cough, which may ultimately result in better treatments for this difficult-to-treat condition." Emilsson and his colleagues ...

Occasional patients with chronic sinusitis who use intranasal ... He has been a practicing physician for 30 years. Ransom JH. Sinusitis: Diagnosis and Treatment. MedGenMed 1(1), 1999 [formerly ...

If action isn't taken now, Ontario's hospital system will not be able to cope with the influx of chronic illness cases in the next two decades, Anthony Dale, OHA president, told CBC Toronto.

The data published in The Lancet is being heralded as a big breakthrough in the treatment of cervical cancer and uses readily available chemotherapy drugs, given to patients before they receive ...

(Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis ...

As I reflect on how we can more effectively bring treatments to patients, one central question emerges: How can we transform scientific discoveries into better treatments? The intersection of ...

(IN BRIEF) GSK plc has announced positive results from its Phase III ANCHOR trials for depemokimab, a biologic treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). The trials demonstrated ...

The overall incidence and severity of treatment-emergent adverse events ... nasal polyp growth and nasal obstruction.” CRSwNP is a chronic condition that affects up to 4% of the general ...

Depemokimab helped reduce nasal obstruction and polyp size for patients who have chronic rhinosinusitis with nasal polyps, a common condition that GSK said affects up to 4% of the population.